Ongoing 23 May 2023

VIKTORIA-1

Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of Gedatolisib plus Fulvestrant with or without Palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.

Enquire

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Breast

Study Phase

III

Trial Identifiers

Registration number: NCT05501886

https://clinicaltrials.gov/study/NCT05501886

GenesisCare Location(s)

St Andrew's Hospital (Oncology)

Principal Investigator(s)

Dr Nick Murray

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

VIKTORIA-1

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare

Website policies

Contact us

Media & Social